These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11520198)

  • 41. Design and validation of the first cell-impermeant melatonin receptor agonist.
    Gbahou F; Cecon E; Viault G; Gerbier R; Jean-Alphonse F; Karamitri A; Guillaumet G; Delagrange P; Friedlander RM; Vilardaga JP; Suzenet F; Jockers R
    Br J Pharmacol; 2017 Jul; 174(14):2409-2421. PubMed ID: 28493341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands.
    Yous S; Durieux-Poissonnier S; Lipka-Belloli E; Guelzim H; Bochu C; Audinot V; Boutin JA; Delagrange P; Bennejean C; Renard P; Lesieur D
    Bioorg Med Chem; 2003 Mar; 11(5):753-9. PubMed ID: 12538005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Strategies leading to MT2 selective melatonin receptor antagonists.
    Spadoni G; Bedini A; Piersanti G; Mor M; Rivara S; Tarzia G
    Adv Exp Med Biol; 2003; 527():577-85. PubMed ID: 15206776
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Functional expression of MT2 (Mel1b) melatonin receptors in human PAZ6 adipocytes.
    Brydon L; Petit L; Delagrange P; Strosberg AD; Jockers R
    Endocrinology; 2001 Oct; 142(10):4264-71. PubMed ID: 11564683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mapping the Melatonin Receptor. 8. Selective MT2 Agonists Derived from 5,6-Dihydroindolo[2,1-a]isoquinolines and Related Systems.
    Tsotinis A; Afroudakis PA; Papanastasiou IP; Sakellaropoulou A; Boniakou M; Komiotis D; Garratt PJ; Delagrange P; Bocianowska-Zbrog A; Sugden D
    ChemMedChem; 2022 Jun; 17(12):e202200129. PubMed ID: 35478275
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis, antioxidant activity and structure-activity relationships for a new series of 2-(N-acylaminoethyl)indoles with melatonin-like cytoprotective activity.
    Spadoni G; Diamantini G; Bedini A; Tarzia G; Vacondio F; Silva C; Rivara M; Mor M; Plazzi PV; Zusso M; Franceschini D; Giusti P
    J Pineal Res; 2006 Apr; 40(3):259-69. PubMed ID: 16499563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors.
    Larraya C; Guillard J; Renard P; Audinot V; Boutin JA; Delagrange P; Bennejean C; Viaud-Massuard MC
    Eur J Med Chem; 2004 Jun; 39(6):515-26. PubMed ID: 15183910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and pharmacological analysis of high affinity melatonin receptor ligands.
    Chu GH; Witt-Enderby PA; Jones M; Pui-Kai L
    Chem Pharm Bull (Tokyo); 2002 Feb; 50(2):272-5. PubMed ID: 11848222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.
    Landagaray E; Ettaoussi M; Leclerc V; Traoré B; Perez V; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
    Bioorg Med Chem; 2014 Feb; 22(3):986-96. PubMed ID: 24417958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis of a small library of phenylalkylamide derivatives as melatoninergic ligands for human mt1 and MT2 receptors.
    Pégurier C; Curtet S; Nicolas JP; Boutin JA; Delagrange P; Renard P; Langlois M
    Bioorg Med Chem; 2000 Jan; 8(1):163-71. PubMed ID: 10968275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands.
    Hu Y; Chan KH; He X; Ho MK; Wong YH
    PLoS One; 2014; 9(12):e113638. PubMed ID: 25479338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Melatonergic properties of the (+)- and (-)-enantiomers of N-(4-methoxy-2,3-dihydro-1H-phenalen-2-yl)amide derivatives.
    Jellimann C; Mathé-Allainmat M; Andrieux J; Renard P; Delagrange P; Langlois M
    J Med Chem; 1999 Mar; 42(6):1100-5. PubMed ID: 10090792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.
    Jeanty M; Suzenet F; Delagrange P; Nosjean O; Boutin JA; Caignard DH; Guillaumet G
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2316-9. PubMed ID: 21420861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands.
    Descamps-François C; Yous S; Chavatte P; Audinot V; Bonnaud A; Boutin JA; Delagrange P; Bennejean C; Renard P; Lesieur D
    J Med Chem; 2003 Mar; 46(7):1127-9. PubMed ID: 12646022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The influence od melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies.
    Juszczak M; Roszczyk M; Kowalczyk E; Stempniak B
    J Physiol Pharmacol; 2014 Dec; 65(6):777-84. PubMed ID: 25554981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.
    Mésangeau C; Fraise M; Delagrange P; Caignard DH; Boutin JA; Berthelot P; Yous S
    Eur J Med Chem; 2011 May; 46(5):1835-40. PubMed ID: 21392858
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.
    Bedini A; Spadoni G; Gatti G; Lucarini S; Tarzia G; Rivara S; Lorenzi S; Lodola A; Mor M; Lucini V; Pannacci M; Scaglione F
    J Med Chem; 2006 Dec; 49(25):7393-403. PubMed ID: 17149869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tetrahydronaphthalenic derivatives as new agonist and antagonist ligands for melatonin receptors.
    Fourmaintraux E; Depreux P; Lesieur D; Guardiola-Lemaître B; Bennejean C; Delagrange P; Howell HE
    Bioorg Med Chem; 1998 Jan; 6(1):9-13. PubMed ID: 9502101
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors.
    Legros C; Brasseur C; Delagrange P; Ducrot P; Nosjean O; Boutin JA
    J Pharmacol Exp Ther; 2016 Mar; 356(3):681-92. PubMed ID: 26759496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives.
    Bedini A; Lucarini S; Spadoni G; Tarzia G; Scaglione F; Dugnani S; Pannacci M; Lucini V; Carmi C; Pala D; Rivara S; Mor M
    J Med Chem; 2011 Dec; 54(24):8362-72. PubMed ID: 22047556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.